Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL‑60 cells

Yang,Huicong; Huang,Yiqun; Zou,Yong; Ma,Xudong

doi:10.3892/ol.2017.6556

Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL‑60 cells

Authors:
- Huicong Yang
- Yiqun Huang
- Yong Zou
- Xudong Ma
View Affiliations

Affiliations: Department of Clinical Laboratory, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China, Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China
Published online on: July 8, 2017 https://doi.org/10.3892/ol.2017.6556
Pages: 3043-3050

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the synergistic effect of phenylhexyl isothiocyanate (PHI) and LY294002 [an inhibitor of phosphoinositide 3‑kinase (PI3K)] on the PI3K/protein kinase B (Akt) signaling pathway, modulating histone acetylation, inhibiting cell viability and inducing apoptosis in HL‑60 cells. The inhibition of HL‑60 cell viability was monitored using an MTT assay. Cell apoptosis was measured using flow cytometry. Expression of acetylated histone H3 and histone H4, and the Akt signaling pathway proteins phosphorylated Akt (p‑Akt), phosphorylated mammalian target of rapamycin (p‑mTOR) and phosphorylated ribosomal protein S6 kinase (p‑p70S6K) was detected using western blotting. The results of the present study identified that PHI and LY294002 were able to inhibit cell viability and induce cell apoptosis in HL‑60 cells. The combination exhibited a synergistic effect on cell viability and apoptosis. PHI treatment led to an accumulation of acetylated histone H3 and histone H4, but LY294002 treatment had no effect on histone acetylation. However, LY294002 was identified to enhance the effect of PHI on histone acetylation in HL‑60 cells. PHI and/or LY294002 were identified to dephosphorylate proteins in the PI3K/Akt signaling pathway, with a synergistic effect observed when used in combination. The results of the present study indicated that the combination of PHI and LY294002 may offer a novel therapeutic strategy for acute myeloid leukemia.

View Figures

View References

1	Löwenberg B, Downing JR and Burnett A: Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999. View Article : Google Scholar : PubMed/NCBI
2	Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B and Herzig GP: High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J Clin Oncol. 7:1260–1267. 1989. View Article : Google Scholar : PubMed/NCBI
3	Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, et al: Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Childrens cancer group study. J Clin Oncol. 12:2367–2377. 1994. View Article : Google Scholar : PubMed/NCBI
4	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kubota Y, Ohnishi H, Kitanaka A, Ishida T and Tanaka T: Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: Direct evidence of PI3K activation. Leukemia. 18:1438–1440. 2004. View Article : Google Scholar : PubMed/NCBI
6	Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS and Ko YW: Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia. 17:995–997. 2003. View Article : Google Scholar : PubMed/NCBI
7	Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 Kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
8	Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB and Andreeff M: Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 18:267–275. 2004. View Article : Google Scholar : PubMed/NCBI
9	Stauffer F, Holzer P and García-Echeverria C: Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents. 5:449–462. 2005. View Article : Google Scholar : PubMed/NCBI
10	Brazil DP, Yang ZZ and Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci. 29:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
11	Hanada M, Feng J and Hemmings BA: Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta. 1697:3–16. 2004. View Article : Google Scholar : PubMed/NCBI
12	Edlind MP and Hsieh AC: PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wang P, Liu N, Pang Q, Qu C, Wang B and Guo H: PI3K/AKT signaling pathway in the regulation of non-small cell lung cancer radiosensitivity after hypofractionated radiation therapy. Int J Radia Oncol Biol Physics. 84:(Suppl). S6702012. View Article : Google Scholar
14	Roche S, Koegl M and Courtneidge SA: The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors. Proc Natl Acad Sci USA. 91:9185–9189. 1994. View Article : Google Scholar : PubMed/NCBI
15	Shivakrupa R, Bernstein A, Watring N and Linnekin D: Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 63:4412–4419. 2003.PubMed/NCBI
16	Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 1:989–997. 2002.PubMed/NCBI
17	Hu H, Jiang C, Li G and Lü J: PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis. 26:1374–1381. 2005. View Article : Google Scholar : PubMed/NCBI
18	Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K and Powis G: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res. 15:1135–1139. 1995.PubMed/NCBI
19	Hu L, Zaloudek C, Mills GB, Gray J and Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 6:880–886. 2000.PubMed/NCBI
20	Semba S, Itoh N, Ito M, Harada M and Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
21	Minarini A, Milelli A, Fimognari C, Simoni E, Turrini E and Tumiatti V: Exploring the effects of isothiocyanates on chemotherapeutic drugs. Expert Opin Drug Metab Toxicol. 10:25–38. 2014. View Article : Google Scholar : PubMed/NCBI
22	Cavell BE, Syed Alwi SS, Donlevy A and Packham G: Anti-angiogenic effects of dietary isothiocyanates: Mechanisms of action and implications for human health. Biochem Pharmacol. 81:327–336. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D and Chiao JW: Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 28:1287–1293. 2006.PubMed/NCBI
24	Xiao L, Huang Y, Zhen R, Chiao JW, Liu D and Ma X: Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol. 123:71–76. 2010. View Article : Google Scholar : PubMed/NCBI
25	Huang YQ, Ma XD, Zhen RJ, Chiao JW and Liu DL: Experiment study of PHI on histone methylation and acetylation in Molt-4 cells. Zhonghua Xue Ye Xue Za Zhi. 28:612–615. 2007.(In Chinese). PubMed/NCBI
26	Jiang S, Ma X, Huang Y, Xu Y, Zheng R and Chiao JW: Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol. 3:482010. View Article : Google Scholar : PubMed/NCBI
27	Zou Y, Ma X, Huang Y, Hong L and Chiao JW: Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol. 5:362012. View Article : Google Scholar : PubMed/NCBI
28	Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA and Martelli AM: The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia. 22:1106–1116. 2008. View Article : Google Scholar : PubMed/NCBI
29	Wang L, Liu D, Ahmed T, Chung FL, Conaway C and Chiao JW: Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol. 24:187–192. 2004.PubMed/NCBI
30	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
31	Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W and Chiao JW: Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res. 26:1225–1230. 2006.PubMed/NCBI
32	Lai YD, Ma XD, Huang YQ, Xu XN, Wang XZ, Chiao DJ and Liu D: Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate. Zhonghua Zhong Liu Za Zhi. 32:804–807. 2010.(In Chinese). PubMed/NCBI
33	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
34	Zhuang Z, Ma X, Huang Y, Zheng Z, Zheng Y and Jiang S: Study on histone acetylation modulation and Akt signaling pathway inhibition by phenyhexyle isothiocyanate in prostate cancer PC3 cell line. Chin J Urol. 31:707–709. 2010.
35	Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, et al: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 10:975–987. 2005. View Article : Google Scholar : PubMed/NCBI
36	West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
37	Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM and Cocco L: Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol. 20:239–252. 2005.PubMed/NCBI
38	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
39	Huang WC and Chen CC: Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol. 25:6592–6602. 2005. View Article : Google Scholar : PubMed/NCBI
40	Rohde JR and Cardenas ME: The tor pathway regulates gene expression by linking nutrient sensing to histone acetylation. Mol Cell Biol. 23:629–635. 2003. View Article : Google Scholar : PubMed/NCBI
41	Denlinger CE, Rundall BK and Jones DR: Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J Thorac Cardiovasc Surg. 130:1422–1429. 2005. View Article : Google Scholar : PubMed/NCBI
42	Wang X, Sun DF and Fang JY: Research advances on the relationship of PI3-kinase/Akt/mTOR pathway and epigenetic modification. Yi Chuan. 28:1585–1590. 2006.(In Chinese). View Article : Google Scholar : PubMed/NCBI
43	Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li T, Hattori N, Wang D, Du Y, Song B, et al: Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy. 11:2309–2322. 2015. View Article : Google Scholar : PubMed/NCBI
44	Nishioka C, Ikezoe T, Yang J, Koeffler HP and Yokoyama A: Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia. 22:2159–2568. 2008. View Article : Google Scholar : PubMed/NCBI
45	Gan YH and Zhang S: PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol. 45:e150–e154. 2009. View Article : Google Scholar : PubMed/NCBI
46	Sakamoto K, Iwasaki K, Sugiyama H and Tsuji Y: Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell. 20:1606–1617. 2009. View Article : Google Scholar : PubMed/NCBI
47	Pan L, Lu J, Wang X, Han L, Zhang Y, Han S and Huang B: Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer. 109:1676–1688. 2007. View Article : Google Scholar : PubMed/NCBI